Plus, a beaten-down fintech stock with a favorable risk-reward profile, our Goldman Sachs-backed bull thesis, and Morgan Stanley’s 125% upside data center pick.
Plus, William Blair’s memory “supercycle” winner, a stock Morgan Stanley says has “ongoing execution issues”, Netflix’s new deal, the top IPOs of tomorrow, and more.
Plus, a doubled price target from Aletheia, potential beneficiaries of the latest tariff delay, and much more.
Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Plus, dual double-downgrades, a crypto firm with 130% implied upside, and much more.
The secret sauce behind silver’s rally, Wells Fargo’s new pick for AI “super-cycle” leader, Huber Research’s grim view on the Netflix-WBD deal, and much more.
This company could be poised to benefit from one of the most important industrial realignments in the US today.
An income investment for the new rate environment, a massive IPO announcement, an 'overdone' AI selloff, and more.
A beaten-down sector quietly being transformed by AI, a firm 'uniquely positioned' within the Trump administration, and much more.
The energy tail risk no one’s talking about, why a retail giant got double-downgraded, a candidate for the next IPO pop, and more.
This week in Street Sheet Research: a six-week market rally hits a wall amid AI fatigue, Datadog barks back with post-earnings upgrades, and the U.S. redraws its critical minerals map. Plus, what Polymarket’s long-awaited U.S. debut could mean for prediction markets everywhere.
Plus, our weekly report covers Nvidia’s quantum leap, a tech giant’s unsung 'second monopoly', and more.
Plus, an attractive opportunity amid a 'minefield for investors', a slew of price target hikes across the crypto sector, and more.
Plus, a biotech with 'potentially game-changing' trial results, the 'too far, too fast' rally you might still be betting on, and more.
Plus, who could win from OPEC’s latest production target hike, Baird’s pick for the “AI juggernaut for the information age”, and more.
Plus, why markets shrugged off news of the shutdown, sweeping pharmaceutical developments in DC, and dueling analyst calls on Apple
Our first-ever premium research report is here: a truly global macro shift, and two ways to play it.
A sudden development in the genetic-editing sector, another wild week for Nvidia, and much more.
America is aging. Here's how to play it.
A bold Nvidia investment that didn’t grab headlines, a paradigm shift for commodity markets, and more.
Fed cut odds shift, EchoStar–SpaceX deal, Nike/Dick’s calls, BofA downgrade, pharma pressure, streaming shakeup.
Only early access members will get tomorrow's email. Make sure you're on the list.
